Axol at SOT 2018

We would be delighted to meet you

Make sure you stop by:

Our Booth #7
Our Vendor Spotlight Presentation (find out more)
Our Poster Spotlight Presentation (find out more)
Our Poster (find out more)

Vendor Spotlight

Presented by Axol Bioscience

"Discover how human iPSC-derived neural cells can advance your drug discovery research"

Wednesday April 18, 2018
09:40
The Boulind Suite
Presenter: Dr Zoe Nilsson, Product Manager, Axol Bioscience

Spotlight Overview

Dr. Zoe Nilsson will speak on human iPSC-derived Microglia as well as other recent developments in iPSC technology and how these are advancing research into neurodegenerative diseases, neuropathic pain and improving the prediction of neurotoxicity.

Poster Spotlight

Axol's hiPSC-derived Microglia on the spot

"Characterisation of in vitro models of microglia function to support neuroinflammation drug discovery"

Tuesday April 17, 2018
12:20 - 13:20
Poster 6
The Boulind Suite
Presenter: Dr Meera Raja, Senior Scientist, Sygnature Discovery

Spotlight Overview

Dr. Meera Raja will present the latest data from Axol's human iPSC-derived Microglia, which are currently under development.

Poster

New data on human iPSC-derived Sensory Neurons

"In vitro characterization of human induced pluripotent stem cell-derived Sensory Neurons"

Wednesday April 18, 2018
12:40 - 13:40
Poster 28
The Boulind Suite
Presenter: Dr Zoe Nilsson, Product Manager, Axol Bioscience

Poster Overview

Dr. Zoe Nilsson will present data on the characterization of hiPSC-derived Sensory Neurons assessing the expression and function of the DRG-specific voltage-gated sodium channels (Nav1.7, Nav1.8 and Nav1.9) and transient receptor potential (TRP) ion channels, TRPV1, TRPA1 and TRPM8. Functional responses were evaluated against typical pain inducing molecules and chemotherapy drugs. This data provides an in-depth characterization of Axol’s hiPSC-derived Sensory Neurons demonstrating a viable human cell-culture model for pioneering research and drug discovery on both nociceptive and neuropathic pain disorders.


Share this post:

Axol Bioscience launches human antibodies

Society of Toxicology (SOT) 2018